Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab

BACKGROUND: Overweight and obese patients with solid tumors receiving anti-programmed cell death-1 (PD-1)/PD-ligand-1(PD-L1) immune checkpoint inhibitors exhibit improved survival and higher risk of immune-related adverse events (irAEs) than those with a normal body mass index (BMI). In classic Hodg...

Descripción completa

Detalles Bibliográficos
Autores principales: De Filippi, Rosaria, Morabito, Fortunato, Santoro, Armando, Tripepi, Giovanni, D’Alò, Francesco, Rigacci, Luigi, Ricci, Francesca, Morelli, Emanuela, Zinzani, Pier Luigi, Pinto, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638339/
https://www.ncbi.nlm.nih.gov/pubmed/34852840
http://dx.doi.org/10.1186/s12967-021-03134-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638339/
https://www.ncbi.nlm.nih.gov/pubmed/34852840
http://dx.doi.org/10.1186/s12967-021-03134-4

Ejemplares similares